The NYT piece on MON covers no new ground, and it repeats the canard that glyphosate resistance renders MON’s biotech traits less consequential. I’ve previously posted why it doesn’t.
My desire for tomorrow’s earnings report is merely the absence of another reduction in EPS guidance.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.